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Background: Biotin-responsive basal ganglia disease (BBGD) is an autosomal recessive neurometabolic disorder. It is
characterized by sub acute encephalopathy with confusion, seizure, dysarthria and dystonia following a history of
febrile illness. If left untreated with biotin, the disease can progress to severe quadriparesis and even death.
Method: A retrospective chart review of 18 patients with BBGD from two tertiary institutions describing their
clinical, magnetic resonance imaging and molecular findings was conducted.
Result: Eighteen children from 13 families seen over a period of nine years (2003–2012) were included. (Age range:
14month to 23 years, M: F: 1:1). The clinical features included sub acute encephalopathy, ataxia (n= 18), seizures
(n= 13) dystonia (n=12) ,dysarthria (n= 9), quadriparesis and hyperreflexia (n=9). Magnetic resonance imaging
demonstrated abnormal signal intensity with swelling in the basal ganglia during acute crises (n= 13/13)
and atrophy of the basal ganglia and necrosis during follow up (n= 13/13). One-third of the present patients
showed the recurrence of acute crises while on biotin therapy alone, but after the addition of thiamine, crises did
not recur. All of the patients have a homozygous missense mutation in exon 5 of the SLC19A3 gene. The frequency
of acute crises, delay in diagnosis and initiation of treatment significantly influenced the outcome. On follow up,
four patients died, two had spastic quadriplegia, six had normal outcome and the rest had speech and motor
dysfunctions.
Conclusion: Clinicians should suspect BBGD in any child presenting with sub acute encephalopathy, abnormal
movement and MRI findings as described above. Both biotin and thiamine are essential for disease management.
Since biotin alone could not prevent the recurrence of crises in some patients, a more appropriate term to describe
the disease would be biotin-thiamine-responsive basal ganglia disease (BTBGD).
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Biotin-responsive basal ganglia disease (BBGD), also
known as thiamine metabolism dysfunction syndrome-2
(THMD2) (MIM: 607483), is an autosomal recessive
inherited neurometabolic disorder. BBGD was first de-
scribed by Ozand et al. in 10 patients, of whom 8 were
Saudi, 1 was Syrian and 1 was Yemeni. The disease is
characterized by sub acute encephalopathy with confu-
sion, dysarthria and dysphagia with occasional supra-
nuclear facial nerve palsy or external ophthalmoplegia
that progresses to severe cogwheel rigidity, dystonia and
quadriparesis with a vague history of febrile illness [1]. In
2005, the disease was mapped to chromosome 2q36.3 and
was found to result from a mutation in the SLC19A3 gene
that encodes hTHTR2, a second thiamine-transporter [2].
Subsequently, cases have been reported in patients of dif-
ferent ethnicities including those of Lebanese, Portuguese,
Indian and Japanese origins [3-6]. Neuroradiological find-
ings include bilateral abnormal signal intensity in the basal
ganglia with swelling during acute crises [1,3-6], specific-
ally in the central part of the caudate heads and in part or
all of the putamen [1]. Additionally, abnormal signal in-
tensity in the thalami [6], globi pallidi [3], white [1], and
brain and cerebellar atrophy [6] are also observed.
BBGD responds to the administration of high doses of
biotin (5–10 mg/kg/day) [1,3-6], and the symptoms re-
appear within 1 month if biotin is discontinued [1]. Al-
though the probands did not respond to thiamine,
carnitine, phenobarbital or diazepam treatment in the
original report [1], the patients showed improvement
with the addition of thiamine to the biotin therapy in
another reports [5,6].
Thus far, only 20 cases of BBGD have been described
worldwide, and there are anecdotal reports in the litera-
ture regarding the natural history of the disease, its
neurological outcomes and the genotype-phenotype cor-
relation [1,3-6].
In this study, we report the natural history, genotype-
phenotype correlation, biochemical and molecular find-
ings, features on Magnetic Resonance Imaging (MRI) and
the importance of thiamine in the treatment regimen of
this disease. This large cohort of patients affected with this
disease and their results should contribute to the under-
standing of the natural history and treatment of this dev-
astating neurometabolic disease.
Method
A retrospective chart review of BBGD patients attending
the Biochemical Genetics (Metabolic) and Neurology
clinics between 2003 and 2012 was conducted. All BBGD
patients from King Abdulaziz Medical City (KAMC) and
King Khalid University Hospital (KKUH), Riyadh, Saudi
Arabia, were included in the study. The diagnosis of
BBGD was confirmed in all living participants and in onedeceased individual based on DNA molecular testing. This
study was approved by the ethics review boards of all par-
ticipating institutions.
Result
In total, 18 patients were included (15 from KAMC and
3 from KKUH). Table 1, Table 2 and Table 3 summarize
the demographic information and the results of clinical,
molecular and treatment regimens for all patients. All
patients were Saudi and the male to female ratio was
1:1. The oldest patient was 23 years old with moderate
motor and speech deficits, while the youngest was 15
months old with normal development.
Clinical history and examination
Consanguinity was confirmed in 17 of the 18 (95%) pa-
tients. Eight patients were from three families (see Table 1),
and 9 of the 18 (50%) patients had a positive family history
of a similarly affected sibling. Thirteen of the 18 (72%) pa-
tients came from the same tribe.
The age of onset is variable, but onset commonly occurs
between 3 and 4 years (45%). All patients presented with
the classical clinical features of subacute encephalopathy
(confusion, drowsy, altered level of consciousness) and
ataxia triggered by febrile illness. Seizures occurred in 13
of the 18 (72%) patients, and the seizures were mainly
partial or generalized tonic-clonic seizures. Neurological
examination showed: extrapyramidal sign dystonia and/or
dysarthria were found in 12 of the 18 (67%) patients.
quadriparesis and hyperreflexia in 9 of 18 (50%). Fundus
examination were normal in all patients.
Investigations
All of the following were unremarkable which includes:
lactate level in blood and CSF, ammonia, biotinidase,
creatine phosphokinase, acylcarnitine profile, copper,
ceruloplasmin, blood for biotin and thiamine level,
plasma aminoa acids, urine for amino acids, urine for
organic acids, liver enzymes, coagulation profile, lipid
profile and cerebrospinal fluid for cell counts, protein,
glucose and culture. Magnetic resonance imaging fin-
dings (see Figure 1) consisted of abnormal signal
intensity at the caudate and putamen with diffuse in-
volvement of the brain including the cortical and sub-
cortical white matter and the infratentorial region,
while atrophy and necrosis of the basal ganglia was
demonstrated in all patients who had MRIs during
chronic follow-up. Cerebellar, thalami and brain stem
involvement were confirmed in 4 of the 13 (31%) pa-
tients, while one patient had a spinal lesion with in-
creased T2 signal intensity, particularly in the cervical
region. Fifteen of the 18 (83%) patients were diagnosed
based on DNA molecular testing, and all were found to
have the same homozygous missense mutation in exon
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Table 1 Demographics, clinical features, long term outcome of the cohort (Continued)
10 F 11 yrs 5
months
Yes No SAE, loose
milestones,
dystonia
No Yes Spastic quadriplegic 5 Biotin 10
mg/kg/day
1 year Had recurrence of crises on Biotin












Retrospectively diagnosed based on
diagnosis of his younger sibling.
12 F 4 yrs 3 yrs Yes No SAE, ataxia ,
loose mile
stones














14 M 6 yrs 4 yrs Yes No SAE, ataxia,
dysarthria,
dystonia








15 M Died at 3.5
yrs
3 yrs Yes Yes SAE, ataxia,
dysarthria,
dystonia




Retrospectively diagnosed based on
diagnosis of his younger sibling.
16 F 13 yrs 11 yrs Yes No SAE, ataxia
dysarthria,
dystonia



















18 F 2 yrs and 9
months




Retrospectively diagnosed based on
diagnosis of her younger sibling.



















Table 2 Summary of the results
Result # (%)
Age of onset 3-4 years (8/18; 45%)
Consanguinity 17/18 (95%)
One tribe 13/18 (72%)
Saudi 18/18 (100%)
c.1264 A>G (p.T422A) mutation in exon 5 of SLC19A3 gene 15/15 (100%)
SAE, ataxia triggered by febrile illness 18/18 (100%)
Seizure 13/18 (72%)
Mild-moderate neurological deficit mainly speech and motor 6/18 (33%)
Normal 6/18 (33%)
Spastic quadriplegic 2/18 (11%)
Death 4/18 (22%)
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heterozygous for this mutation. The remaining three
patients were diagnosed retrospectively after the diag-
nosis of their younger siblings.Follow up and outcome
In 8 of the 18 (45%) patients, the diagnosis was delayed,
while immediate diagnosis was achieved in 7 individuals.
Four of the 18 (22%) patients died. Three patients died
because treatment was not initiated due to lack of
diagnosis. One patient who was diagnosed died at 26
years of age following an acute crisis; he had been
receiving biotin therapy for 18 years. One-third of the
patients showed mild to moderate neurological deficit,
mainly in speech and motor function; one-third of the
patients were normal; and two patients had severe global
neurological deficits and spastic quadriplegia. In general,
the cognitive outcome is better than speech and motor
outcomes. All diagnosed patients improved with biotin
(5–10 mg/kg/day) therapy while alive. The maximum
dose of biotin was used 12 mg/kg/day, the dose schedule
range from 1–3 times daily with no consistent regimen
and the tablet strength was 10mg tablet. Six of the 18
(33%) patients had a recurrence of acute crises while on
biotin alone, but after the addition of thiamine, there
were no recurrences of those crises.Table 3 MRI findings
Results
In acute crises: high signal T2 with swelling in basal ganglia (caudate and pau
white matters and infratentorial brain.
In chronic follow up: high signal T2 in basal ganglia (caudate and pautamen)
Thalami
Brain stem – all 4 patients had midbrain involvement and one had medulla o
Cerebellum – all 4 patients had cortical involvement, and it was more diffuse
Spine – cervical spinal cordDiscussion
In this study, we report the largest cohort to date of pa-
tients with BBGD. Our results support the findings of
previous reports regarding the classical clinical presenta-
tion, the high prevalence of this disease in Saudi Arabia
compared to other countries, the deterioration and death
of patients who do not receive biotin treatment, auto-
somal recessive inheritance, the importance of biotin in
treatment regimens and the cause of the disease in a
mutation of the SLC19A3 gene, which was found in all
patients [1,3-6]. Our study demonstrated the following
important points:The natural history and the dosage regimens for biotin
and/or thiamine in BBGD patients are incompletely
understood
Previous reports showed highly variable neurological
outcomes even among siblings from the same family
[1,3-6]. Ozand et al. reported that 5 of 10 (50%) patients
with BBGD were normal with 5–10 mg/kg/day of biotin
over a variable period of follow-up ranging from 5 to 10
years [1], while 5 mg/kg/day of biotin was ineffective in
another report, and the patient was bedridden [6]. Inter-
estingly, one BBGD child responded well to lower do-
sages of biotin (5–30 mg/day) [3]. Furthermore, Debs
et al. reported on two siblings with BBGD, a 33 year old# (%)
tamen) diffuse cortical, subcortical 13/13 (100%)
with atrophy and necrosis 13/13 (100%)
4/13 (31%)
blongata as well. 4/13 (31%)
in one patient. 4/13 (31%)
1/13 (7.6%)
Figure 1 MRI brain axial T2 weighted spin echo images – (images A to F) and MRI spine sagittal T2 weighted image – (image G). Upper
column: (A, B, C) was done for the patient during the acute crisis. A: This image shows high T2 signal and swelling of substantia nigra
(at midbrain), and signal abnormality with swelling of right inferior frontal gyrus in the cortical and subcortical region. B: It shows high T2 signal
and swelling of lentiform, caudate head with small necrotic changes and involvement of medial thalami. C: It shows focal high T2 cortical signal
and subcortical white matter signal at both frontal and parietal lobes. Lower column: (D, E, F) was done as a follow up exam for the same patient
during chronic stage of the disease. D: This image was done at the level of the midbrain and shows focal high T2 fluid signal in the substantia
nigra which evolved from swelling seen during the acute crisis (image A). E: It shows high T2 (fluid signal) and atrophy in the basal ganglia
(lentiform and caudate nuclei) indicates evolved swelling into necrosis. F: It shows interval resolution of the cortical and subcortical signal seen
during the acute crisis at the frontal lobes. MRI Image of the spine (G) shows patchy high T2 intramedullary signal most conspicuous in the
cervical spinal cord with swelling extends from C3 to C7 vertebral level.
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man responded well to biotin alone, while the woman
did not improve until thiamine was added to the treat-
ment regimen. This significant heterogeneity demon-
strates the complexity and ambiguity of the natural
history and treatment of BBGD. Furthermore, this co-
hort demonstrated intrafamilial heterogeneity as we ob-
serve different outcomes within siblings of the same
family, same environments and same molecular findings
(see Table 1). However, the favorable outcome could be
related to early initiation of treatment in several of them.
Thiamine and biotin are essential in the treatment
regimens of BBGD
In original reports, thiamine was not effective [1]. How-
ever, one-third of the patients reported in this cohort
showed recurrence of acute crises while on biotin alone,
but with the addition of thiamine, the recurrence of these
crises was prevented. This result supports the hypothesis
that the impairment of thiamine transport in the brain has
a critical role in this disorder. Furthermore, the SLC19A3
gene encodes hTHTR2, a second thiamine-transporter
and not a biotin transporter [2]. In fact, hTHTR2 demon-
strates 48% structural identity to hTHTR1, which is also athiamine transporter, while demonstrating only 17% iden-
tity with hSMVT, which is a known biotin transporter [7].
Additionally, Subramanian et al. proved that biotin is not
a substrate for hTHTR2 [7]. This evidence supports the
importance of thiamine in the treatment of this disease
but leaves the mechanism by which BBGD patients im-
proved dramatically on biotin, as we observed in 100%
of our cohort, unclear. However, it could be hypothesized
that the biotin and thiamine transporters in the basal
ganglia are closely associated and thus act synergistically
[7]. Therefore, we recommend that the treatment regimen
for patients with BBGD contain both thiamine and biotin.
Factors contributing to clinical outcome
The gap between the age of disease onset and the date
of diagnosis correlates directly with the neurological
outcome. Eight of the 18 patients who had a delayed
diagnosis displayed mild to moderate neurological defi-
cits, while seven patients who were diagnosed immedi-
ately achieved normal development. Another important
factor is the number of attacks of acute crises, as a poor
outcome is directly associated with more acute crises in
the present patients. All those children with normal out-
come had only one event. Additionally, the immediate
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that contributes to normal outcomes, as reported cohort
showed no recurrence of crises on this regimen for a
period of up to 5 years of follow-up. However, it is very
difficult to extrapolate firm conclusion with regards to
aforementioned factors as the median follow up of normal
children were 16 months (1 month-3 year) which is too
short compare to poorer outcome individuals.Magnetic resonance imaging commonly shows an effect
in the basal ganglia and could involve other parts of the
brain and spinal cord
In the original report by Ozand et al., the MRI findings
consist of bilateral necrosis in the basal ganglia, particu-
larly at the central part of the caudate heads and part or
all of the putamen with severe edema during the acute cri-
sis in addition to white matter involvement at the grey–
white matter junction [1]. Subsequent reports confirmed
these findings and added the involvement of the globi
pallidi, thalami, cerebellum and brain stem [3,6]. Our lar-
gest cohort demonstrated these findings and showed ab-
normal signal intensity and swelling at the caudate and
pautamen with diffuse involvement of the brain including
the cortical, subcortical white matter and infratentorial
region, while atrophy and necrosis of the basal ganglia
appeared during chronic follow-up. Cerebellar, thalami
and brain stem involvement are found in one-third of pa-
tients (see Figure 1). Interestingly, one patient demon-
strated spinal cord involvement with increased T2 signal
intensity particularly at the cervical region, which was not
reported previously. This could be easily explained by the
fact that previous patients did not undergo MRI of the
spine, and neither did the patients in this report. It would
be valuable to perform spinal MRI for all patients affected
with this disease to see the extent of this finding.The genotype-phenotype correlation is poor
All current patients have a homozygous missense mutation
in exon 5 of the SLC19A3 gene [c.1264 A>G (p.T422A)].
This mutation is a founder mutation in Saudi families, be-
cause all of the patients of Saudi origin reported as having
BBGD also carry this mutation. Other reported mutations
in the SLC19A3 gene include a homozygous missense
mutation in exon 5 of the gene [c.68 G>T (p.G23 V)] in a
Yemeni family; a homozygous missense mutation in exon
3 of the gene [c.958 G>C (p.E320Q0] reported in four
Japanese patients who are biotin unresponsive; a frame
shift mutation in exon 2 [c.74dupT(p.Ser26 LeufsX19)];
and an intron mutation (c.980-14 A>G), which was discov-
ered in 2 siblings in a heterozygous state of European an-
cestry. Despite having the same mutation, children from
the same family have extremely variable outcomes, ranging
from normal to severely handicapped [1-3,5,6].Future directions
Despite its discovery 14 years ago, several questions re-
garding BBGD remain unanswered. Animal models are
vital to understanding the pathophysiology of thiamine
and biotin transport in the brain, particularly the levels
of biotin and thiamine in the brain at the basal ganglia.
This information is critical to understanding the clinical
picture, complications and management of this disease.
Moreover, investigators should make an effort to find
a biomarker for this disease, which will help to accur-
ately determine the appropriate dosages of biotin and
thiamine to consequently improve the outcome of the
disease. Finally, diagnosing more asymptomatic cases
through the screening of high risk tribes and inter-
national registries to accommodate more cases of the
SLC19A3 gene defect will lead to a better understanding
of the natural history of the disease and will facilitate
well designed treatment and outcome studies.
Conclusion
Based on the evidence obtained from our cohort, we re-
commend changing the name BBGD to biotin-thiamine-
responsive basal ganglia disease (BTBGD). Clinicians
should consider this disorder in any patients with sub-
acute/acute encephalopathy, ataxia triggered by febrile ill-
ness and basal ganglia involvement.
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